Leukemia inhibitory factor: A paracrine mediator of bone metabolism

Growth Factors

Volumn 30, Issue 2, 2012, Pages 76-87

  Sims, Natalie A ^a   Johnson, Rachelle W ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

chondrocyte; gp130; Leukemia inhibitory factor; oncostatin M; osteoblast; osteoclast

Indexed keywords

ALKALINE PHOSPHATASE; CCAAT ENHANCER BINDING PROTEIN DELTA; COLLAGENASE 3; ESTROGEN RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SH2; RETINOIC ACID; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ARTHRITIS; ARTICULAR CARTILAGE; BINDING AFFINITY; BONE DESTRUCTION; BONE GROWTH; BONE METABOLISM; BONE MINERALIZATION; CANCER GROWTH; CARTILAGE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GROWTH PLATE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; T LYMPHOCYTE; TRABECULAR BONE; TUMOR GROWTH; VASCULARIZATION;

ANIMALS; BONE AND BONES; BONE DISEASES; CHONDROCYTES; CYTOKINE RECEPTOR GP130; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MICE; OSTEOBLASTS; OSTEOGENESIS;

EID: 84858971170     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.656760     Document Type: Review

References (117)

1. Abe E, Ishimi Y, Takahashi N, Akatsu T, Ozawa H, Yamana H, Yoshiki S, Suda T. 1988. A differentiation-inducing factor produced by the osteoblastic cell line MC3T3-E1 stimulates bone resorption by promoting osteoclast formation. J Bone Miner Res 3:635-645. (Pubitemid 19042550)
2. Allan EH, Hilton DJ, Brown MA, Evely RS, Yumita S, Metcalf D, Gough NM, Ng KW, Nicola NA, Martin TJ. 1990. Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol 145:110-119.
3. Askmyr M, Sims NA, Martin TJ, Purton LE. 2009. What is the true nature of the osteoblastic hematopoietic stem cell niche? Trends Endocrinol Metab 20:303-309.
4. Aubert J, Dessolin S, Belmonte N, Li M, McKenzie FR, Staccini L, Villageois P, Barhanin B, Vernallis A, Smith AG, Ailhaud G, Dani C. 1999. Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade. J Biol Chem 274:24965-24972.
5. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543. (Pubitemid 32184286)
6. Barton BE, Murphy TF. 2000. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: Implications for pathophysiology of myeloma. Cytokine 12:1537-1545.
7. Bellido T, Borba VZ, Roberson P, Manolagas SC. 1997. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138:3666-3676. (Pubitemid 27351915)
8. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC. 1996. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest 97:431-437.
9. Belmonte N, Phillips BW, Massiera F, Villageois P, Wdziekonski B, Saint-Marc P, Nichols J, Aubert J, Saeki K, Yuo A, Narumiya S, Ailhaud G, Dani C. 2001. Activation of extracellular signal-regulated kinases and CREB/ATF-1 mediate the expression of CCAAT/enhancer binding proteins beta and delta in preadipocytes. Mol Endocrinol 15:2037-2049. (Pubitemid 33022539)
10. Berg M, Fraker DL, Alexander HR. 1994. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 6:425-432. (Pubitemid 24263888)
11. Bonewald LF, Johnson ML. 2008. Osteocytes, mechanosensing and Wnt signalling. Bone 42:606-615.
12. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, Hummel O, Hubner N, Savatier P. 2009. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 27: 1760-1771.
13. Boyle K, Zhang JG, Nicholson SE, Trounson E, Babon JJ, McManus EJ, Nicola NA, Robb L. 2009. Deletion of the SOCS box of suppressor of cytokine signalling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. Cell Signal 21:394-404.
14. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF. 2008. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454:221-225. (Pubitemid 351969891)
15. Bravo J, Heath JK. 2000. Receptor recognition by gp130 cytokines. Embo J 19:2399-2411. (Pubitemid 30323530)
16. Broholm C, Pedersen BK. 2010. Leukaemia inhibitory factor - an exercise-induced myokine. Exercise Immunol Rev 16:77-85.
17. Clahsen T, Lehmann U, Stross C, Hermanns HM, Volkmer-Engert R, Schneider-Mergener J, Heinrich PC, Schaper F. 2005. The tyrosine 974 within the LIF-R-chain of the gp130/LIF-R heteromeric receptor complex mediates negative regulation of LIF signalling. Cell Signal 17:559-569. (Pubitemid 40430959)
18. Cormier-Daire V, Munnich A, Lyonnet S, Rustin P, Delezoide AL, Maroteaux P, Le Merrer M. 1998. Presentation of six cases of Stuve-Wiedemann syndrome. Pediatr Radiol 28:776-780. (Pubitemid 28479580)
19. Cornish J, Callon K, King A, Edgar S, Reid IR. 1993. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology 132:1359-1366. (Pubitemid 23068660)
20. Cornish J, Callon KE, Edgar SG, Reid IR. 1997. Leukemia inhibitory factor is mitogenic to osteoblasts. Bone 21:243-247. (Pubitemid 27404082)
21. Croker BA, Kiu H, Nicholson SE. 2008. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19:414-422.
22. Dagoneau N, Scheffer D, Huber C, Al-Gazali LI, Di Rocco M, Godard A, Martinovic J, Raas-Rothschild A, Sigaudy S, Unger S, Nicole S, Fontaine B, Taupin JL, Moreau JF, Superti-Furga A, Le Merrer M, Bonaventure J, Munnich A, Legeai-Mallet L, Cormier-Daire V. 2004. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am J Hum Genet 74:298-305. (Pubitemid 38168617)
23. Dazai S, Akita S, Hirano A, Rashid MA, Naito S, Akino K, Fujii T. 2000. Leukemia inhibitory factor enhances bone formation in calvarial bone defect. J Craniofac Surg 11:513-520. (Pubitemid 34863528)
24. Derigs HG, Boswell HS. 1993. LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells. Leukemia 7:630-634. (Pubitemid 23139869)
25. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. 1998. Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48:165-174. (Pubitemid 28156361)
26. Douglas AM, Goss GA, Sutherland RL, Hilton DJ, Berndt MC, Nicola NA, Begley CG. 1997. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 14:661-669. (Pubitemid 27095857)
27. Emery B, Merson TD, Snell C, Young KM, Ernst M, Kilpatrick TJ. 2006. SOCS3 negatively regulates LIF signalling in neural precursor cells. Mol Cell Neurosci 31:739-747.
28. Escary JL, Perreau J, Dumenil D, Ezine S, Brulet P. 1993. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 363:361-364. (Pubitemid 23161534)
29. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. 1991. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 78:1476-1484.
30. Falconi D, Aubin JE. 2007. LIF inhibits osteoblast differentiation at least in part by regulation of HAS2 and its product hyaluronan. J Bone Miner Res 22:1289-1300. (Pubitemid 351339711)
31. Falconi D, Oizumi K, Aubin JE. 2007. Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells. Stem Cells 25:305-312. (Pubitemid 46232784)
32. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G. 2010. Insulin signalling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142: 296-308.
33. Flanagan AM, Horton MA, Dorey EL, Collins DA, Evely RS, Moseley JM, Firkin FC, Chambers TJ, Helfrich MH, Martin TJ. 1992. An assessment of the ability of human bone marrow cultures to generate osteoclasts. Int J Exp Pathol 73:387-401.
34. Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T. 1997. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 14:751-761. (Pubitemid 27100019)
35. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. 2008. OSM, LIF its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest 26:222-229. (Pubitemid 351328998)
36. Gearing DP, Gough NM, King JA, Hilton DJ, Nicola NA, Simpson RJ, Nice EC, Kelso A, Metcalf D. 1987. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 6:3995-4002.
37. Geng Y, Blanco FJ, Cornelisson M, Lotz M. 1995. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J Immunol 155:796-801.
38. Gimble JM, Wanker F, Wang CS, Bass H, Wu X, Kelly K, Yancopoulos GD, Hill MR. 1994. Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein. J Cell Biochem 54:122-133. (Pubitemid 24073739)
39. Grant SL, Douglas AM, Goss GA, Begley CG. 2001. Oncostatin M and leukemia inhibitory factor regulate the growth of normal human breast epithelial cells. Growth Factors 19:153-162. (Pubitemid 34065697)
40. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. 1998. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943-951. (Pubitemid 28173356)
41. Greenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. 1993. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res 8:1163-1171. (Pubitemid 23308109)
42. Grimaud E, Blanchard F, Charrier C, Gouin F, Redini F, Heymann D. 2002. Leukaemia inhibitory factor (LIF) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Cytokine 20:224-230. (Pubitemid 37163475)
43. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR, Ihle JN, Kerr IM. 1995. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 14:1421-1429.
44. Hakeda Y, Sudo T, Ishizuka S, Tanaka K, Higashino K, Kusuda M, Kodama H, Kumegawa M. 1991. Murine recombinant leukemia inhibitory factor modulates inhibitory effect of 1,25 dihydroxyvitamin D3 on alkaline phosphatase activity in MC3T3-E1 cells. Biochem Biophys Res Commun 175:577-582.
45. Hall J, Guo G, Wray J, Eyres I, Nichols J, Grotewold L, Morfopoulou S, Humphreys P, Mansfield W, Walker R, Tomlinson S, Smith A. 2009. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 5:597-609.
46. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signalling through the gp130/ Jak/STAT pathway. Biochem J 334(Pt 2):297-314. (Pubitemid 28448572)
47. Henrotin YE, De Groote DD, Labasse AH, Gaspar SE, Zheng SX, Geenen VG, Reginster JY. 1996. Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cartilage 4:163-173. (Pubitemid 26334016)
48. Heymann D, Gouin F, Guicheux J, Munevar JC, Godard A, Daculsi G. 1997. Upmodulation of multinucleated cell formation in long-term human bone marrow cultures by leukaemia inhibitory factor (LIF). Cytokine 9:46-52. (Pubitemid 27148367)
49. Hilton DJ, Nicola NA, Gough NM, Metcalf D. 1988. Resolution and purification of three distinct factors produced by Krebs ascites cells which have differentiation-inducing activity on murine myeloid leukemic cell lines. J Biol Chem 263:9238-9243.
50. Hilton DJ, Nicola NA, Waring PM, Metcalf D. 1991. Clearance and fate of leukemia-inhibitory factor (LIF) after injection into mice. J Cell Physiol 148:430-439. (Pubitemid 21926079)
51. Hirai H, Karian P, Kikyo N. 2011. Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem J 438:11-23.
52. Hogan JC, Stephens JM. 2005. Effects of leukemia inhibitory factor on 3T3-L1 adipocytes. J Endocrinol 185:485-496. (Pubitemid 40883394)
53. Huyton T, Zhang JG, Luo CS, Lou MZ, Hilton DJ, Nicola NA, Garrett TP. 2007. An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc Natl Acad Sci USA 104:12737-12742. (Pubitemid 47255224)
54. Ishimi Y, Abe E, Jin CH, Miyaura C, Hong MH, Oshida M, Kurosawa H, Yamaguchi Y, Tomida M, Hozumi M, Suda T. 1992. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): Regulation of its production and possible roles in bone metabolism. J Cell Physiol 152:71-78.
55. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, Kishimoto T, Suda T. 1990. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297-3303.
56. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA. 2011. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signalling. Cancer Res 71:822-831.
57. Jung C, Dagoneau N, Baujat G, Le Merrer M, David A, Di Rocco M, Hamel B, Megarbane A, Superti-Furga A, Unger S, Munnich A, Cormier-Daire V. 2010. Stuve-Wiedemann syndrome: Longterm follow-up and genetic heterogeneity. Clin Genet 77:266-272.
58. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. 1996. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer 66:515-519. (Pubitemid 26176769)
59. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. (Pubitemid 28180851)
60. Lai CF, Ripperger J, Morella KK, Wang Y, Gearing DP, Fey GH, Baumann H. 1995. Separate signalling mechanisms are involved in the control of STAT protein activation and gene regulation via the interleukin 6 response element by the box 3 motif of gp130. J Biol Chem 270:14847-14850.
61. Lindberg RA, Juan TS, Welcher AA, Sun Y, Cupples R, Guthrie B, Fletcher FA. 1998. Cloning and characterization of a specific receptor for mouse oncostatin M. Mol Cell Biol 18:3357-3367. (Pubitemid 28240508)
62. Liu F, Aubin JE, Malaval L. 2002. Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: Differential regulation by dexamethasone and LIF. Bone 31:212-219. (Pubitemid 34754450)
63. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935. (Pubitemid 40994212)
64. Lotz M, Moats T, Villiger PM. 1992. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest 90:888-896.
65. Lowe C, Gillespie GA, Pike JW. 1995. Leukemia inhibitory factor as a mediator of JAK/STATactivation in murine osteoblasts. J Bone Miner Res 10:1644-1650.
66. Lu Y, Feng JQ. 2011. FGF23 in skeletal modeling and remodeling. Curr Osteoporosis Rep 9:103-108.
67. Lu X, Kang Y. 2009. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci USA 106:9385-9390.
68. Malaval L, Aubin JE. 2001. Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. J Cell Biochem Suppl Suppl 36:63-70.
69. Malaval L, Gupta AK, Aubin JE. 1995. Leukemia inhibitory factor inhibits osteogenic differentiation in rat calvaria cell cultures. Endocrinology 136:1411-1418.
70. Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q, Kolbe S, Gordon IR, Wang H, Egan G, Murray S, Butzkueven H, Kilpatrick TJ. 2008. Leukemia inhibitory factor signalling modulates both central nervous system demyelination and myelin repair. Glia 56:686-698.
71. Marshall MK, Doerrler W, Feingold KR, Grunfeld C. 1994. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology 135:141-147. (Pubitemid 24203810)
72. Marusic A, Kalinowski JF, Jastrzebski S, Lorenzo JA. 1993. Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells. J Bone Miner Res 8:617-624. (Pubitemid 23127922)
73. McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JM, Martin TJ, Sims NA. 2010. Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling. Calcif Tissue Int 86:261-270.
74. Menkhorst E, Zhang JG, Sims NA, Morgan PO, Soo P, Poulton IJ, Metcalf D, Alexandrou E, Gresle M, Salamonsen LA, Butzkueven H, Nicola NA, Dimitriadis E. 2011. Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice. PLoS One 6:e19665.
75. Metcalf D, Gearing DP. 1989. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci USA 86:5948-5952. (Pubitemid 19217565)
76. Metcalf JA, Zhang Y, Hilton MJ, Long F, Ponder KP. 2009. Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 97:202-211.
77. Miyazu S, Furuno T, Nakanishi M. 2010. Phosphorylation states of STAT3 and ERKs in mouse embryonic stem cells. Cell Biol Int 34:485-492.
78. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D. 1996. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signalling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-32643. (Pubitemid 27008685)
79. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. 2011. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234.
80. Nemoto O, Yamada H, Mukaida M, Shimmei M. 1996. Stimulation of TIMP-1 production by oncostatin M in human articular cartilage. Arthritis Rheum 39:560-566. (Pubitemid 26118032)
81. Noda M, Vogel RL, Hasson DM, Rodan GA. 1990. Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells. Endocrinology 127:185-190. (Pubitemid 20228119)
82. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. 2011. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26: 1012-1021.
83. Oskowitz AZ, Lu J, Penfornis P, Ylostalo J, McBride J, Flemington EK, Prockop DJ, Pochampally R. 2008. Human multipotent stromal cells from bone marrow and microRNA: Regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci USA 105:18372-18377.
84. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G. 2011. Endocrine regulation of male fertility by the skeleton. Cell 144:796-809.
85. Palmqvist P, Persson E, Conaway HH, Lerner UH. 2002. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169:3353-3362. (Pubitemid 35013185)
86. Plun-Favreau H, Perret D, Diveu C, Froger J, Chevalier S, Lelievre E, Gascan H, Chabbert M. 2003. Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor. J Biol Chem 278:27169-27179. (Pubitemid 36876873)
87. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM. 1996. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 11:754-759.
88. Poulton IJ, McGregor NE, Pompolo S, Walker EC, Sims NA. in press. Contrasting roles of LIF in murine bone development and remodeling involve region-specific changes in vascularization. J Bone Miner Res. doi: 10.1002/jbmr.1485
89. Rathjen PD, Nichols J, Toth S, Edwards DR, Heath JK, Smith AG. 1990. Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations. Genes Dev 4:2308-2318. (Pubitemid 120026264)
90. Reid LR, Lowe C, Cornish J, Skinner SJ, Hilton DJ, Willson TA, Gearing DP, Martin TJ. 1990. Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology 126:1416-1420. (Pubitemid 20095743)
91. Rodan SB, Wesolowski G, Hilton DJ, Nicola NA, Rodan GA. 1990. Leukemia inhibitory factor binds with high affinity to preosteoblastic RCT-1 cells and potentiates the retinoic acid induction of alkaline phosphatase. Endocrinology 127:1602-1608. (Pubitemid 20315215)
92. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT. 2000. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 43:821-826.
93. Sabatakos G, Sims NA, Chen J, Aoki K, Kelz MB, Amling M, Bouali Y, Mukhopadhyay K, Ford K, Nestler EJ, Baron R. 2000. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985-990.
94. Sakata T, Iwagami S, Tsuruta Y, Yamaguchi M, Michishita M, Nagata K, Takai Y, Ogata M, Teraoka H, Fujiwara H. 1992. Constitutive expression of leukemia inhibitory factor (LIF) mRNA and production of LIF by a cloned murine thymic stromal cell line. Thymus 19:89-95.
95. Shiina-Ishimi Y, Abe E, Tanaka H, Suda T. 1986. Synthesis of colony-stimulating factor (CSF) and differentiation-inducing factor (D-factor) by osteoblastic cells, clone MC3T3-E1. Biochem Biophys Res Commun 134:400-406. (Pubitemid 16145348)
96. Shin JE, Park SH, Jang YK. 2011. Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer. Mol Cells 31:181-189.
97. Sims NA, Chia LY. in press. Regulation of sclerostin expression by paracrine and endocrine factors. Clin Rev Bone Miner Metab. doi:10.1007/s12018- 011-9121-7
98. Sims NA, Gooi JH. 2008. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 19:444-451.
99. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ. 2004. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signalling pathways. J Clin Invest 113:379-389. (Pubitemid 38544182)
100. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263:92-95. (Pubitemid 24076263)
101. Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR. 2006. The hedgehog signalling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66:7548-7553. (Pubitemid 44289210)
102. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, Abbondanzo SJ. 1992. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359: 76-79.
103. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90:11924-11928. (Pubitemid 24008752)
104. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA. 2011. Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30:3036-3048.
105. Tian X, Jee WS, Li X, Paszty C, Ke HZ. 2011. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48:197-201.
106. Tomida M, Yamamoto-Yamaguchi Y, Hozumi M. 1984. Characterization of a factor inducing differentiation of mouse myeloid leukemic cells purified from conditioned medium of mouse Ehrlich ascites tumor cells. FEBS Lett 178:291-296. (Pubitemid 15199592)
107. Upadhyay A, Sharma G, Kivivuori S, Raye WS, Zabihi E, Carroll GJ, Jazayeri JA. 2009. Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes. Cytokine 46:332-338.
108. Van de Loo FA, Arntz OJ, Van den Berg WB. 1997. Effect of interleukin 1 and leukaemia inhibitory factor on chondrocyte metabolism in articular cartilage from normal and interleukin-6- deficient mice: Role of nitric oxide and IL-6 in the suppression of proteoglycan synthesis. Cytokine 9:453-462. (Pubitemid 27312246)
109. Varghese S, Yu K, Canalis E. 1999. Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts. Am J Physiol 276:E465-E471. (Pubitemid 29157400)
110. Villiger PM, Geng Y, Lotz M. 1993. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 91: 1575-1581. (Pubitemid 23127359)
111. Villiger PM, Terkeltaub R, Lotz M. 1992. Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. J Clin Invest 90: 488-496.
112. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA. 2008. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 23:2025-2032.
113. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA. 2010. Oncostatin M promotes bone formation independently of resorption when signalling through leukemia inhibitory factor receptor in mice. J Clin Invest 120:582-592.
114. Walker EC, Poulton IJ, McGregor NE, Ho PWM, Allan E, Quach JM, Martin TJ, Sims NA. In Press. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect. J Bone Miner Res. doi: 10.1002/jbmr.1506
115. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, Gliniak BC, McKenna HJ, Papayannopoulou T, Thoma B, Cheng L, Donovan PJ, Peschon JJ, Bartlett PF, Willis CR, Wright BD, Carpenter MK, Davison BL, Gearing DP. 1995. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121:1283-1299.
116. Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R. 1991. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol 19:347-351.
117. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. 2011. Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241.